WALTHAM, Mass. — Trinity Life Sciences has revealed a breakthrough in early disease detection with the unveiling of a new artificial intelligence and machine learning (AIML) model that can identify Type 1 diabetes (T1D) at least one year before a clinical diagnosis. The announcement was made during the American Diabetes Association’s 85th Scientific Sessions, where the study was featured as a late-breaking poster presentation.
The study, titled Identification of Earlier Stage Autoimmune Type 1 Diabetes Using Machine Learning Algorithms, was conducted by Trinity Life Sciences in collaboration with global healthcare company Sanofi. The research leveraged a retrospective cohort design, combining anonymized healthcare claims and laboratory data to train and validate a predictive model capable of identifying individuals at high risk of progressing to stage 3 T1D.
The AIML model was developed using data from both pediatric and adult populations confirmed to have T1D. It demonstrated the ability to detect signs of the disease at least a year before diagnosis, with a built-in 12-month blinded period. According to Trinity, the model not only maintained strong accuracy but also prioritized sensitivity to capture as many true positive cases as possible while reducing false positives.
Clare Gora, Partner and Head of Data Strategy & Analytics at Trinity Life Sciences, emphasized the model’s potential to transform diabetes screening and care. “We are thrilled to collaborate with Sanofi on this groundbreaking study,” Gora said. “At Trinity, we believe the intersection of AI technologies, life sciences expertise and data is where true innovation happens.”
The model also produced some surprising insights. Notably, it proved more likely to identify T1D in adults than in children, a finding that contrasts with current healthcare practices, which often emphasize pediatric onset. The study suggests that this approach could help modernize T1D screening strategies by targeting individuals at higher risk and ultimately improving patient outcomes.
Trinity’s latest advancement adds to a growing wave of AI applications aimed at transforming early detection and preventive care in chronic disease management.
